MLNT - Melinta Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
99,606
96,430
33,864
18,016
27,309
Cost of Revenue
38,386
41,057
-
-
0
Gross Profit
61,220
55,373
-
-
27,309
Operating Expenses
Research Development
32,358
55,409
49,475
81,686
93,353
Selling General and Administrative
120,615
133,312
63,325
53,538
22,871
Total Operating Expenses
151,961
182,893
112,800
135,224
116,224
Operating Income or Loss
-90,741
-127,520
-78,936
-117,208
-88,915
Interest Expense
39,532
43,179
7,624
1,228
2,206
Total Other Income/Expenses Net
-5,273
12,777
27,489
-753
-2,198
Income Before Tax
-134,692
-157,192
-58,916
-117,961
-91,113
Income Tax Expense
-
-
-
-
-
Income from Continuing Operations
-134,692
-157,192
-58,916
-117,961
-91,113
Net Income
-134,692
-157,192
-58,916
-117,961
-91,113
Net Income available to common shareholders
-134,692
-157,192
-78,175
-117,961
-91,113
Reported EPS
Basic
-
-17.12
-109.30
-58.50
-52.25
Diluted
-
-17.12
-109.30
-58.50
-52.25
Weighted average shares outstanding
Basic
-
9,182
715
2,013
1,743
Diluted
-
9,182
715
2,013
1,743
EBITDA
-
-97,112
-50,841
-117,208
-88,915